Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2019 / Cilt: 43 - Sayı: 1

OXIDATIVE STRESS AND PARKINSON DISEASE

OKSİDATİF STRES VE PARKİNSON HASTALIĞI

Pages
94–116
Publication Date
2019-01-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Avoiding damage products due to oxidative stress and drawing a protective treatment protocol may be a crucial strategy for maintaining healthy brain function and protecting the organism from neurodegenerative diseases such as Parkinson's disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Parkinson's Disease (PD) is a chronic and progressive neurodegenerative disease in the brain associated with the loss of dopaminergic neurons.
📊
Key Findings & Data:Old age is the only proven factor in the development of PD.
💡
Conclusion & Impact:Avoiding damage products due to oxidative stress and drawing a protective treatment protocol may be a crucial strategy for maintaining healthy brain function and protecting the organism from neurodegenerative diseases such as Parkinson's disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Parkinson's disease (PD) · oxidative stress · reactive oxygen species (ROS)

Abstract

Objective: Parkinson's Disease (PD) is a chronic and progressive neurodegenerative disease in the brain associated with the loss of dopaminergic neurons. Old age is the only proven factor in the development of PD. It is thought that oxidative stress which is more triggered in old age plays a vital role in the formation of dopaminergic neurotoxicity. In this review, the relationship between oxidative stress and PD will be examined. Material and Method: The databases in the health sciences field were used to compile the studies conducted to determine the relationship between PH and oxidative stress. Previously published articles such as Web of Science have been used. Result and Discussion: Parkinson's is a neurodegenerative disease resulting from the complex interaction of genetic and environmental factors that affect on many basic cellular process. Oxidative stress threatens genetic integrity and contributes to the development of PH. Avoiding damage products due to oxidative stress and drawing a protective treatment protocol may be a crucial strategy for maintaining healthy brain function and protecting the organism from neurodegenerative diseases such as Parkinson's disease.

Özet

Amaç: Parkinson Hastalığı (PH) beyinde dopaminerjik nöronların kaybıyla ilişkili kronik ve progresif nörodejeneratif bir hastalıktır. Yaşlılık tüm nörodejeneratif hastalıklarda olduğu gibi PH’nın oluşumunda da kanıtlanmış tek faktördür. Yaşlılıkta daha fazla tetiklenen oksidatif stresin dopaminerjik nörotoksisite oluşumunda önemli bir rol oynadığı düşünülmektedir. Bu derlemede oksidatif stres ve PH arasındaki ilişki irdelenecektir. Gereç ve Yöntem: PH ile oksidatif stres arasındaki ilişkinin tespiti için yapılmış çalışmaların kapsamlı olarak derlenebilmesi için sağlık bilimleri alanındaki veri tabanları kullanılmıştır. Web of Science gibi temel atıf indekslerinde daha önce yayımlanmış makalelerden yararlanılmıştır. Sonuç ve Tartışma: Parkinson çok sayıda temel hücresel süreci etkileyen genetik ve çevresel faktörlerin kompleks etkileşiminden kaynaklanan nörodejeneratif bir hastalıktır. Oksidatif stres genetik bütünlüğü tehdit eder ve PH’nın gelişimine katkı sağlar. Oksidatif strese bağlı olarak meydana gelen hasar ürünlerinden kaçınmak ve bu çizgide koruyucu tedavi protokolü çizmek sağlıklı beyin fonksiyonlarının devamı ve organizmayı Parkinson gibi nörodejeneratif hastalıklardan korumak adına önemli bir strateji olabilir.

🔖

Cite This Article

ASLAN, S. N., KARAHALİL, B. (2019). OXIDATIVE STRESS AND PARKINSON DISEASE. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 43 - Sayı: 1, 94–116. https://ajindex.com/articles/88686

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Hipkiss, A.R. (2007). Biological aspects of ageing. El Sevier Psychiatry, 6(12), 476-79, https://doi.org/10.1016/j.mppsy.2007.09.003.
  2. Skinner, J.S. (2005). Exercise testing and exercise prescription for special cases: theoretical basis and clinical application, (Ed.), Lippincott Williams & Wilkins, Baltimore. Amor, S., Peferoen, L.A., Vogel, D.Y., Breur, M., van der Valk, P., Baker, D., van Noort J.M. (2013). Inflammation in neurodegenerative diseases – an update. Immunology,142,151-166
  3. Radak, Z., Zhao, Z., Goto, S., Koltai, E. (2011). Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Molecular Aspect of Medicine, 32, 305-315
  4. Aydın, A. (2015) Oksidanlar&Antioksidanlar. Yeditepe Üniversitesi Sağlık Bilimleri Enstitüsü, Turkheltox Toksikoloji Kongresi; 2015 Ekim 21-24;
  5. İzmir.
  6. Dorsey, E.R., Constantinescu, R., Thompson J.P., Biglan, K.M., Holloway R.G., Kieburtz K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A., Tanner, C.M. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 68 (5), 384-6
  7. Willis, A., Evanoff, B.A., Lian, M., Criswell, S.R., Racetta, B.A. (2010). Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. Neuroepide, 4 (3), 143-51
  8. Olanow, C.W., Brundin, P. (2013). Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder? Movement Disorders, 28(1), 31-4. Retrieved February 6,2013 from https://doi.org/10.1002/mds.25373.
  9. Olanow, C.W., Kordower, J.H., Lang, A.E., Obeso, J.A. (2009). Dopaminergic transplantation for Parkinson’s disease: Current status and future prospects. Annals of Neurology, 66 (5), 591-6
  10. Kalia, L.V., Lang, A.E. (2015). Parkinson’s Disease. Lancet, 386 (9996), 896-912
  11. Gazewood, J.D., Richard, D.R.,Clebak, K. (2013). Parkinson Disease: an update. Am.Fam.Physician, 87 (4), 267-273
  12. Hou, Y., Zhang, J., Chen, B., Wu, T. (2015). Local brain activity in different motor subtypes of Parkinson's disease with fMRI, Europe PMC, 95 (7), 483-8
  13. Connoly, B.S., Lang, A.E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA, 311 (16), 1670-83.
  14. Lev, N., Melamed, E. (2001). Heredity in Parkinson's Disease: New Findings. IMAJ, 3, 435-438
  15. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219 (4587), 979-80.
  16. Richards, R. I, Robertson, S. A, O'Keefe,